Dear suebell: The large U.S. clinical trials addressing the use of Herceptin in early breast cancer used an every 3 week schedule of AC followed by Taxol with Herceptin. There was a small study done at Memorial Sloan Kettering suggesting that it is probably safe to use the every 2 week chemotherapy scheduling, but the two approaches have not been directly compared in this situation; both approaches are commonly used. A recently reported study comparing taxol to taxotere (without Herceptin) following AC chemotherapy found no significant differences between the two for the treatment of early breast cancer (although more side effects were seen with the taxotere). The decision of which drugs and schedules must be considered in terms of the individual patient. Without evaluation, we cannot provide specific recommendations for you.